Proteomics for Biomarker and Drug Discovery

A special issue of Proteomes (ISSN 2227-7382).

Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 329

Special Issue Editors

Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay Powai, Mumbai 400076, India
Interests: clinical proteomics; biomarker discovery in infectious diseases and cancer
Special Issues, Collections and Topics in MDPI journals
Department of Zoology, Faculty of Sciences, University of Allahabad, Uttar Pradesh 211002, India
Interests: mass spectrometry; proteomics; disease biology; neuroscience; COVID-19

Special Issue Information

Dear Colleagues,

Proteomics probes into the entire set of proteins expressed at the moment in a living system or its part thereof. Given that proteins are intermediate phenotypes, quantitative proteomics sheds light on the dynamic behaviour of the proteome in response to an insult and offers direct scientific insights into physiological processes. These distinctions help proteomic investigations focus on biomarker research for various ailments and aid in therapeutic target discovery.

Over the years, the nascent field of proteomics has evolved enormously. Proteomic findings of yesteryears could be summed up in just a few spreadsheets. However, today individual proteomic studies yield “big data” that needs to be analyzed and evaluated using powerful computational tools and machine learning algorithms. These enormous datasets have helped us understand the subtle modifications in proteome and its interactome in response to disease and pathologies. Analysis has also led to the identification of pathways amenable to the therapeutic management of the disease by novel and existing “repurposed” therapeutics

While mass spectrometry is the primary technology used, other applications, such as protein microarray, have also helped glean new information on functional proteomics and plays important role in human pathologies. They have helped further expand the use of proteomics in searching for new biomarkers and novel therapies.

Recent studies on COVID-19 proteomics, in particular, have significantly contributed to identifying biomarker panels for disease severity prediction and identifying the targets for drug repurposing. If these studies are indicative of what is coming, proteomics today has changed the face of biomarker and drug discovery in biomedical research.

With the aim of pushing the frontiers of existing knowledge of proteomics, this Special Issue of Proteomes seeks submissions on all areas of proteomics and proteomics-aided biomarker and drug discovery with a specific focus on its innovative applications to understand challenging biomedical issues.

Dr. Sanjeeva Srivastava
Dr. Arup Acharjee
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Proteomes is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mass spectrometry
  • proteomics
  • drug discovery
  • therapeutic targets
  • drug repurposing
  • protein microarray
  • LC-MS/MS
  • targeted proteomics
  • bioinformatics

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop